Document is current
Any future updates will be listed below
-
Authors
Bui, Linh T. https://orcid.org/0000-0003-3152-8978
Winters, Nichelle I.
Chung, Mei-I
Joseph, Chitra https://orcid.org/0000-0003-2631-9266
Gutierrez, Austin J. https://orcid.org/0000-0003-2977-2189
Habermann, Arun C.
Adams, Taylor S.
Schupp, Jonas C. https://orcid.org/0000-0002-7714-8076
Poli, Sergio https://orcid.org/0000-0001-5442-3189
Peter, Lance M.
Taylor, Chase J.
Blackburn, Jessica B.
Richmond, Bradley W. https://orcid.org/0000-0001-6200-5235
Nicholson, Andrew G.
Rassl, Doris
Wallace, William A. https://orcid.org/0000-0002-4752-7956
Rosas, Ivan O.
Jenkins, R. Gisli https://orcid.org/0000-0002-7929-2119
Kaminski, Naftali https://orcid.org/0000-0001-5917-4601
Kropski, Jonathan A.
Banovich, Nicholas E.
,
Misharin, Alexander V.
Tsankov, Alexander M.
Spira, Avrum
Barbry, Pascal
Brazma, Alvis
Samakovlis, Christos
Shepherd, Douglas P.
Rawlins, Emma L.
Theis, Fabian J.
Griffonnet, Jennifer
Lee, Haeock
Schiller, Herbert B.
Hofman, Paul
Powell, Joseph E.
Schultze, Joachim L.
Whitsett, Jeffrey
Choi, Jiyeon
Lundeberg, Joakim
Kaminski, Naftali
Kropski, Jonathan A.
Banovich, Nicholas E.
Ordovas-Montanes, Jose
Rajagopal, Jayaraj
Meyer, Kerstin B.
Krasnow, Mark A.
Saeb‐Parsy, Kourosh
Zhang, Kun
Lafyatis, Robert
Leroy, Sylvie
Haniffa, Muzlifah
Nawijn, Martijn C.
Nikolić, Marko Z.
van den Berge, Maarten
Kuhnemund, Malte
Marquette, Charles-Hugo
Von Papen, Michael
Eickelberg, Oliver
Rosenblatt-Rosen, Orit
Reyfman, Paul A.
Pe’er, Dana
Horvath, Peter
Tata, Purushothama Rao
Regev, Aviv
Rojas, Mauricio
Seibold, Max A.
Shalek, Alex K.
Spence, Jason R.
Teichmann, Sarah A.
Quake, Stephen
Duong, Thu Elizabeth
Biancalani, Tommaso
Desai, Tushar
Sun, Xin
Zaragosi, Laure Emmanuelle
- License Information
-
More Information
Article History
Received: 1 December 2020
Accepted: 4 June 2021
First Online: 14 July 2021
Competing interests
: J.A.K. has received advisory board fees from Boehringer Ingelheim, Inc, Janssen Pharmaceuticals, is on the scientific advisory board of APIE Therapeutics, and has research contracts with Genentech. In the last 36 months, N.K. reported personal fees from Biogen Idec, Boehringer Ingelheim, Third Rock, Samumed, Numedii, AstraZeneca, Life Max, Teravance, RohBar, and Pliant and Equity in Pliant; collaboration with MiRagen, AstraZeneca; Grant from Veracyte, all outside the submitted work. In addition, N.K. has a patent for New Therapies in Pulmonary Fibrosis, and Peripheral Blood Gene Expression licensed to Biotech. A.G.N. has received advisory board fees from Boehringer Ingelheim, Galapagos, Medical Quantitative Image Analysis and personal fees for educational material from Up to Date and Boehringer Ingelheim. RGJ reports grants from AstraZeneca, grants from Biogen, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees Daewoong, personal fees from Galapagos, grants from Galecto, grants from GlaxoSmithKline, personal fees from Heptares, nonfinancial support from NuMedii, grants and personal fees from Pliant, personal fees from Promedior, non-financial support from Redx, personal fees from Roche, other from Action for Pulmonary Fibrosis, outside the submitted work. All other authors declare no competing interests.
